StockNews.AI
ALGS
StockNews.AI
118 days

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

1. ALGS announced acceptance of eight abstracts for EASL Congress 2025. 2. Research focuses on chronic hepatitis B virus and metabolic dysfunction-associated steatohepatitis. 3. Promising results reported for ALG-000184 and ALG-055009 therapies. 4. Clinical studies highlight sustained HBV DNA suppression and lipid reduction effects. 5. Presentations by notable experts may boost investor confidence in ALGS.

9m saved
Insight
Article

FAQ

Why Bullish?

The acceptance of multiple abstracts suggests strong ongoing R&D momentum, similar to past instances like Gilead's thrive during early hepatitis C presentations.

How important is it?

The abstract acceptance indicates ongoing development and potential breakthrough therapies, which are crucial for investor sentiment and market perception.

Why Short Term?

Market reactions are likely to occur before and during the EASL event in May 2025, reminiscent of swift investor reactions in prior biotech conferences.

Related Companies

GILDVRTXABBV
April 23, 2025 16:05 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. Details on the abstracts are as follows: ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection Abstract #: 861Title: Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV InfectionPresenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong KongDate/Time: May 8, 2025 at 4:15pm – 5:00pm CET; May 8, 2025 at 8:30am – 5:00pm CETSession: Poster Tour; Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Abstract #: 856Title: The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus InfectionPresenter: Professor Jinlin Hou, MD, Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical UniversityDate/Time: May 8, 2025 at 8:30am – 5:00pm CETSession: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Abstract #: 1924Title: Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184Presenter: Andreas Jekle, PhDDate/Time: May 8, 2025 at 8:30am – 5:00pm CETSession: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies ALG-055009: Potential best-in-class small molecule THR-β for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Abstract #: 302Title: ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALDPresenter: Stanley Wang, MD, PhDDate/Time: May 8, 2025 at 9:45am – 10:30am CET; May 10, 2025 at 8:30am – 4:00pm CETSessions: Poster tour; Poster - MASLD: Therapy Abstract #: 2185Title: ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD studyPresenter: Megan Fitzgerald, PhDDate/Time: May 10, 2025 at 8:30am – 4:00pm CETSession: Poster - MASLD: Therapy Abstract #: 2152Title: Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpointsPresenter: Kha Le, PhDDate/Time: May 10, 2025 at 8:30am – 4:00pm CETSession: Poster - MASLD: Therapy Abstract #: 2001Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese micePresenter: Xuan Luong, PhDDate/Time: May 9, 2025 at 8:30am – 5:00pm CETSession: Poster - MASLD: Experimental and pathophysiology Preclinical Abstract #: 2105Title: Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidatesPresenter: Jin Hong, PhDDate/Time: May 9, 2025 at 8:30am – 5:00pm CETSession: Poster - Viral Hepatitis: Experimental and pathophysiology About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Investor ContactAligos Therapeutics, Inc.Jordyn TaraziVice President, Investor Relations & Corporate Communications+1 (650) 910-0427jtarazi@aligos.com Media ContactInizio EvokeJake RobisonVice PresidentJake.Robison@inizioevoke.com

Related News